Five things for pharma marketers to know: Monday, December 12, 2016

Share this content:

1. A generic version of Roche's influenza therapy Tamiflu has arrived in the U.S. The cheaper version of Tamiflu is expected to generate $500 million in savings this year. (Reuters)

2. The American Diabetes Association and the American Association of Clinical Endocrinologists are expected to issue new guidelines reflecting data showing that Eli Lilly's diabetes drug Jardiance can cut cardiovascular risks. Lilly has already launched an unbranded campaign to raise awareness. (Reuters)

3. Alexion Pharmaceuticals named former AstraZeneca CEO David Brennan as its interim CEO. The company, which is undergoing an audit related to internal allegations of deceptive sales practices, said that CEO David Hallal resigned for personal reasons. (WSJ)

4. Bayer partnered with Versant Ventures to launch a stem-cell research company, BlueRock Therapeutics. The venture has $225 million in funding and will focus on developing treatments for patients seeking to regenerate muscle after a heart attack or side effects associated with taking drugs for Parkinson's disease. (WSJ)

5. Some outcomes-based contracts between manufacturers and payers give the manufacturer exclusive or preferred-provider status, which can help generate a steady stream of patients. (Modern Healthcare)

Share this content:
Scroll down to see the next article